1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
BioMEL : a translational research biobank of melanocytic lesions and melanoma
(
- Contribution to journal › Article
-
Mark
Molecular patterns of resistance to immune checkpoint blockade in melanoma
(
- Contribution to journal › Article
- 2023
-
Mark
Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells
(
- Contribution to journal › Article
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
(
- Contribution to journal › Article
- 2022
-
Mark
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
(
- Contribution to journal › Article
-
Mark
Dialysis as a Novel Adjuvant Treatment for Malignant Cancers
(
- Contribution to journal › Scientific review
- 2021
-
Mark
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
(
- Contribution to journal › Article
-
Mark
Surgery of metastatic melanoma after systemic therapy–the SUMMIST trial : study protocol for a randomized controlled trial
(
- Contribution to journal › Letter
-
Mark
Non-radical primary diagnostic biopsies affect survival in cutaneous head and neck melanoma
(
- Contribution to journal › Article
- 2020
-
Mark
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
(
- Contribution to journal › Article